Sign in
Taking people in United StatesNo phase

Early Feasibility Study of the Capstan Medical TMVR System

Key facts

Who runs it
Capstan Medical
Where
Cincinnati, Nashville, and San Francisco, United StatesSee the 3 sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
Nov 2026
Expected to end
Mar 2032
Type of study
Interventional
Treatments tested
  • Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement
Record updated
9 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Age ≥ 18 years at the time of consent
  • Moderate-to-severe or severe mitral regurgitation
  • NYHA II or greater symptoms
  • The participant is considered to be at elevated, but not prohibitive, surgical risk for mitral valve replacement, as determined by the local multi-disciplinary heart team and/or a validated surgical risk assessment tool (e.g., STS PROM)
  • The local multi-disciplinary heart team determines that surgical mitral valve replacement is not the preferred treatment option and that the participant is an appropriate candidate for treatment with the Capstan System
  • The local multi-disciplinary heart team determines that the participant is unsuitable for mitral transcatheter edge-to-edge repair (mTEER) due to anatomical, technical, and/or clinical reasons
  • The local multi-disciplinary heart team deems heart failure management is optimized based on participant characteristics and applicable guidelines
  • Ability and willingness to provide written informed consent prior to any study related procedure(s)

Who cannot take part

  • Prior mitral valve intervention that would interfere with the appropriate placement of the Capstan Valve
  • Any cardiac or vascular procedure performed within 30 days prior to procedure
  • Myocardial infarction within 30 days prior to enrollment
  • Concurrent medical condition with a life expectancy of less than 12 months
  • Participant is on the waiting list for a heart transplant or has had a prior heart transplant
  • Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.))
  • Untreated severe aortic or pulmonic valve disease (stenosis or regurgitation)
  • Untreatable severe right ventricular dysfunction or severe tricuspid valve disease
  • Cardiac resynchronization therapy (CRT) device implanted within 30 days of procedure
  • Active endocarditis, other ongoing infection requiring antibiotic therapy
  • Stroke or transient ischemic attack (TIA) within 30 days of procedure
  • Active peptic ulcer or active gastrointestinal bleeding
  • Known allergy or hypersensitivity to device materials (e.g. nitinol, PET), or a documented allergy to heparin, that cannot be adequately medicated; a history of HIT, or contraindication to required antithrombotic therapies
  • Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits
  • Clinically significant untreated coronary artery disease requiring revascularization
  • Chronic Obstructive Pulmonary Disease (COPD) on continuous O2 therapy
  • Planned cardiac intervention in the next 12 months
  • LVEF < 25%
  • End-stage renal failure on dialysis or eGFR ≤ 25
  • Pregnant (participants of childbearing age are required to have a negative pregnancy test)
  • Anatomic features unsuitable for the Capstan System
  • Inappropriate anatomy for femoral venous introduction and delivery of the Capstan System
  • Severe mitral stenosis
  • Evidence of intracardiac thrombus, vegetation, or mass
  • PASP > 70mmHg or PVR > 5 Wood units after vasodilator challenge
  • Contraindication to or inability to tolerate the protocol-required therapeutic anticoagulation regimen for the 6-months post-procedure period
  • Participant is contraindicated for transesophageal echocardiography (TEE)
  • Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
  • Refusal of blood products

This trial is currently available in United States.

  • The Christ HospitalCincinnati, United StatesContact: Susie FrakesTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Kathryn AdamsNot yet recruiting
  • Kaiser PermanenteSan Francisco, United StatesContact: Cristina Casias-PerezNot yet recruiting

About the trial

What the trial wants to find out

This early feasibility study is evaluating the safety and performance of the Capstan Compass Robotic System™ for transcatheter mitral valve replacement in patients with symptomatic, moderate-to-severe or severe mitral regurgitation who are unsuitable for surgical repair or transcatheter edge-to-edge repair.

The group in the trial

  • TMVRTreatment being tested

    Participants will undergo transcatheter mitral valve replacement

    Treatment: Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 November 2026